950210.KO Prestige BioPharma Limited

Healthcare Biotechnology Korea Stock Exchange
3,900 KRW
Close of Nov 5, 2026
3,610 14,120
Market cap
KRW 234B
P/E
-
P/B
0.56x
ROE
-21.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is 950210.KO undervalued?

Graham number

The Graham number of Prestige BioPharma Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Prestige BioPharma Limited fundamental analysis

No fundamental analysis for Prestige BioPharma Limited yet.

Prestige BioPharma Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Prestige BioPharma Limited

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1…

Full company profile